The Valley Desk

NCT03719898 · Interventional trial

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Overall registry status Withdrawn

Phase 2

Conditions Anaplastic Large Cell Lymphoma, ALK-Positive

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov